Assessing compliance to reporting mandates in glioblastoma-related clinical trials
For GBM-related trials, noncompliance with reporting mandates remains a major issue. Reporting within 12 months was only 13%. No factors influenced reporting by 12 months, but multiple factors influenced five-year reporting. Further research is needed to understand these associations and create targeted incentives to increase transparency through timely reporting of GBM-related trials.
Authors
- Sherief A. Ghozy (ORCID: https://orcid.org/0000-0001-5629-3023)
- Nicholas A. S. Kendall (ORCID: https://orcid.org/0009-0007-2479-7818)
- Kogulavadanan Arumaithurai (ORCID: https://orcid.org/0000-0003-3169-7050)
- Julian S. Rechberger (ORCID: https://orcid.org/0000-0002-0855-3297)
- David F. Kallmes (ORCID: https://orcid.org/0000-0002-8495-0040)
- Mark Cwajna (ORCID: https://orcid.org/0009-0007-5243-6817)
- Abdelrahman M. Hamouda (ORCID: https://orcid.org/0009-0007-3609-7229)
Institutions
- Mayo Clinic (US)
- University of South Dakota (US)
- WinnMed (US)
- Mayo Clinic in Florida (US)
- American University of the Caribbean School of Medicine (SX)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1371/journal.pone.0323109
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00